Mistletoe Therapy

Mistletoe therapy is a botanical treatment used in integrative oncology to support the immune system, enhance the effectiveness of conventional cancer therapies, and improve overall well-being. Research has shown that mistletoe contains active compounds that promote apoptosis, or programmed cancer cell death, while also stabilizing and repairing DNA that may be damaged by chemotherapy and radiation. Additionally, mistletoe has anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels that tumors rely on for growth. It also works as a protein synthesis inhibitor, which may slow the ability of cancer cells to multiply. One of its most significant benefits is its ability to modulate the immune system, strengthening the body’s natural defenses while reducing inflammation and improving treatment tolerance.

No, mistletoe therapy is not intended to replace standard cancer treatments but rather to complement them. It is used alongside chemotherapy, radiation, surgery, and immunotherapy to help patients better tolerate these therapies and recover more efficiently. Mistletoe has been shown to reduce common side effects such as fatigue, nausea, and inflammation, making it easier for patients to complete their prescribed treatments while maintaining a better quality of life.

Mistletoe therapy works by stimulating key components of the immune system, including macrophages, natural killer (NK) cells, and T-cells, all of which play essential roles in identifying and destroying cancer cells. It also increases cytokine production, boosting immune signaling pathways that help regulate the body’s defense mechanisms. Studies have shown that mistletoe can enhance both Th1 and Th2 cytokine responses, leading to a more balanced and effective immune attack against tumor cells. Over time, patients may experience improved immune resilience, with a gradual increase in healthy lymphocyte levels and enhanced ability to fight off infections.

One of mistletoe’s most important functions is its ability to shield immune cells from the damaging effects of chemotherapy and radiation. It has been shown to protect NK cells, which are responsible for targeting and eliminating cancer cells, from treatment-related depletion. Additionally, mistletoe therapy can increase neutrophil counts, which are often suppressed by chemotherapy, helping to support immune function and reduce the risk of infection. Over the course of treatment, it may also promote the recovery of non-malignant lymphocytes, which play a role in long-term immune health. Because immune monitoring is essential during cancer therapy, mistletoe can serve as an important tool in maintaining overall immune balance.

Mistletoe therapy has been studied in a wide range of solid tumors, including breast, lung, colorectal, pancreatic, prostate, and ovarian cancers.

Studies show that mistletoe therapy is particularly beneficial to those with solid tumor cancers or hematologic malignancies from stage zero through stage four.

It is often used to support patients undergoing active treatment, those in remission seeking recurrence prevention, and individuals in palliative care looking to enhance comfort and well-being​.

However, mistletoe therapy is typically not recommended for patients with acute leukemia.

The most common method of administration is subcutaneous injection (under the skin), typically three times per week. In certain cases, other administration methods, such as intravenous (IV), intratumoral, or intracavitary injections, may be used under clinical supervision​.

Most patients tolerate mistletoe therapy well. Mild redness or swelling at the injection site is common and considered a sign of an appropriate immune response.

Occasionally, flu-like symptoms such as mild fever, fatigue, or body aches may occur. These symptoms typically subside as the body adapts to treatment​.

Yes, but with caution. Since immunotherapy also works by stimulating the immune system, mistletoe therapy must be carefully monitored to prevent excessive immune activation. Close supervision by an integrative oncologist ensures these therapies work synergistically rather than competitively​.

Unlike some immune-stimulating therapies that can exacerbate autoimmune conditions, mistletoe has an immune-modulating effect, meaning it helps regulate immune function rather than overstimulating it. When administered appropriately, mistletoe therapy is generally safe for individuals with autoimmune disorders such as rheumatoid arthritis, lupus, and Hashimoto’s thyroiditis. However, dosing must be carefully monitored to prevent excessive immune activation. Importantly, mistletoe has also been shown to be safe for patients with lymphomas and lymphocytic leukemia, conditions that typically require cautious immune support.

No. Studies indicate that mistletoe therapy does not negatively interfere with chemotherapy or radiation. In fact, it may help patients tolerate these treatments better by reducing their toxicity and side effects​. However, it is essential to discuss mistletoe therapy with your oncology team to ensure it aligns with your treatment plan.

Item The duration of mistletoe therapy varies depending on the individual’s treatment goals. Some patients use it throughout active cancer treatment, while others continue it long-term for immune support and recurrence prevention. Therapy plans are customized and regularly reassessed to optimize benefits​.

Yes. Research and clinical experience suggest that mistletoe therapy is safe for extended use under medical supervision. Long-term use may help maintain immune function and support ongoing cancer surveillance​.

Mistletoe therapy is not currently covered by most insurance providers. However, we strive to make it accessible by offering transparent pricing and personalized guidance on sourcing and affordability​.

Yes. After the initial dose is administered in-office to ensure patient safety and comfort, most patients can self-administer subcutaneous injections at home. Detailed instructions and ongoing support from our clinical team help ensure proper technique​.

Mistletoe therapy requires ongoing monitoring, individualized dosing adjustments, and integrative oncology expertise to ensure safety and effectiveness. Because of this, it is exclusively available to CIOFM members, who receive personalized care and close follow-ups as part of their treatment plan​.